OFATUMUMAB (Kesimpta) prior authorization at Humana
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Humana requires CD20-directed Cytolytic Antibody prior-authorization documentation for OFATUMUMAB (Kesimpta): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Humana reviews OFATUMUMAB (Kesimpta) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Humana's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
OFATUMUMAB (Kesimpta)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring oral DMT first
- Step therapy requiring ocrelizumab first within anti-CD20 class
- Self-administration concerns
- Specialty pharmacy network restriction
Brand: Kesimpta. Anti-CD20 monoclonal antibody for relapsing MS. Self-administered monthly subQ — distinct positioning vs ocrelizumab (IV every 6 months).
Manufacturer patient-assistance program: Novartis Patient Assistance Foundation — relevant when a Humana denial sticks and the patient needs bridge access while appealing.
How Humana approaches Biologic drugs (mAbs and biosimilars) PAs
For OFATUMUMAB (KESIMPTA), check whether the current Humana Biologic drugs (mAbs and biosimilars) policy cites ma plan step therapy on part b drugs or prior auth on specialty drugs. Pharmacy-benefit review for OFATUMUMAB (KESIMPTA) at Humana is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Humana; if denied, use the filing date and route printed on that denial notice. Humana's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Humana is domiciled in KY, so unresolved appeals escalate to the KY insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.humana.com/provider) with the same packet plus an applicable, current clinical source supporting OFATUMUMAB (Kesimpta)for the patient's indication.
Medicare Advantage cases may have plan reconsideration and independent-review steps. Confirm the current level, forwarding rule, and any expedited pathway directly in the notice before selecting an escalation route.
Humana Medicare Advantage organization determinations operate under 42 CFR Part 422 Subpart D. For OFATUMUMAB (KESIMPTA), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. The applicable decision period and any Independent Review Entity routing depend on the request type, current rule, and plan notice. Record the cited source and version, then verify the operational due date against the current notice and CMS materials before relying on it.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Humana denial on DenialHelp.
Contact Humana
- Provider portal: https://www.humana.com/provider
Frequently asked questions
What documentation does Humana need for OFATUMUMAB (Kesimpta) prior auth?
Humana's typical PA packet for OFATUMUMAB (Kesimpta): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Humana?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for OFATUMUMAB (Kesimpta) at Humana?
Preparation scenarios to check against the current notice and policy include: MA plan step therapy on Part B drugs; Skilled nursing facility days; Prior auth on specialty drugs. These are not measured frequency claims. For OFATUMUMAB (Kesimpta), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Humana typically require before approving OFATUMUMAB (KESIMPTA)?
Humana's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For OFATUMUMAB (KESIMPTA), attach the specific disease-activity instrument Humana accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). External-review escalation for Humana fully-insured policies sits with the KY insurance department.
How do I prep for a peer-to-peer with Humana on OFATUMUMAB (Kesimpta)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the OFATUMUMAB (Kesimpta) PA packet
Open ApprovalHelp — generate a OFATUMUMAB (Kesimpta) prior-auth packet tailored to Humana's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com